Patents by Inventor Ian Andrew Yule

Ian Andrew Yule has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA polymerase theta inhibitor for treatment of cancer
    Patent number: 12162895
    Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: December 10, 2024
    Assignee: Breakpoint Therapeutics GmbH
    Inventors: Andrea Guerrero Corella, Stuart Robert Flanagan, Jonathan Hollick, Julien Gilbert Jacques Malassis, Matthew Raymond Smith, Ian Andrew Yule, Jonathan Mark Bentley
  • Compounds, compositions, and therapeutic uses thereof
    Patent number: 12145945
    Abstract: The present invention relates to a compound of the Formula: and pharmaceutically salts thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: November 19, 2024
    Assignee: Breakpoint Therapeutics GmbH
    Inventors: Andrea Guerrero Corella, Stuart Robert Flanagan, Jonathan Hollick, Julien Gilbert Jacques Malassis, Matthew Raymond Smith, Ian Andrew Yule, Jonathan Mark Bentley
  • NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF
    Publication number: 20240336628
    Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 10, 2024
    Inventors: Andrea Guerrero Corella, Stuart Robert Flanagan, Jonathan Hollick, Julien Gilbert Jacques Malassis, Matthew Raymond Smith, Ian Andrew Yule, Jonathan Mark Bentley
  • DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER
    Publication number: 20240327431
    Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Andrea Guerrero Corella, Stuart Robert Flanagan, Jonathan Hollick, Julien Gilbert Jacques Malassis, Matthew Raymond Smith, Ian Andrew Yule, Jonathan Mark Bentley
  • NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF
    Publication number: 20240327430
    Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Andrea Guerrero Corella, Stuart Robert Flanagan, Jonathan Hollick, Julien Gilbert Jacques Malassis, Matthew Raymond Smith, Ian Andrew Yule, Jonathan Mark Bentley
  • Fused imidazole and pyrazole derivatives as modulators of TNF activity
    Patent number: 9868749
    Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 16, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Prafulkumar Tulshibhai Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule
  • Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity
    Publication number: 20160297837
    Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 13, 2016
    Inventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Praful Tulshi Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule